The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Synthetic small inhibiting RNAs: Efficient tools to inactivate oncogenic mutations and restore p53 pathways
Open accessAbstract
Single base pair mutations that alter the function of tumor suppressor genes and oncogenes occur frequently during oncogenesis. The guardian of the genome, p53, is inactivated by point mutation in more than 50% of human cancers. Synthetic small inhibiting RNAs (siRNAs) can suppress gene expression in mammalian cells, although their degree of selectivity might be compromised by an amplification mechanism. Here, we demonstrate that a single base difference in siRNAs discriminates between mutant and WT p53 in cells expressing both forms, resulting in the restoration of WT protein function. Therefore, siRNAs may be used to suppress expression of point-mutated genes and provide the basis for selective and personalized antitumor therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In 2002, a single base difference was found between wtp53 and mutp53, demonstrating that synthetic siRNAs are efficient tools to inactive oncogenic mutations and restore p53 pathways.573”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [573]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
Role for a bidentate ribonuclease in the initiation step of RNA interference
Bernstein, E., Caudy, A. A., Hammond, S. M., & Hannon, G. J. (2001) · Nature · doi:10.1038/35053110 · Cited by 5,018
A System for Stable Expression of Short Interfering RNAs in Mammalian Cells
Brummelkamp, T. R., Bernards, R., & Agami, R. (2002) · Science · doi:10.1126/science.1068999 · Cited by 4,295
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
RNA interference is mediated by 21- and 22-nucleotide RNAsPreprint
Elbashir, S. M., Lendeckel, W., & Tuschl, T. (2001) · Genes & Development · doi:10.1101/gad.862301 · Cited by 3,354
Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate
Elbashir, S. M., Martinez, J., Patkaniowska, A., Lendeckel, W., & Tuschl, T. (2001) · The EMBO Journal · doi:10.1093/emboj/20.23.6877 · Cited by 1,469
Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding
Garrus, J. E., von Schwedler, U. K., Pornillos, O. W., Morham, S. G., Zavitz, K. H., Wang, H. E., Wettstein, D. A., Stray, K. M., Côté, M., Rich, R. L., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00506-2 · Cited by 1,369
On the Role of RNA Amplification in dsRNA-Triggered Gene Silencing
Sijen, T., Fleenor, J., Simmer, F., Thijssen, K. L., Parrish, S., Timmons, L., Plasterk, R. H. A., & Fire, A. Z. (2001) · Cell · doi:10.1016/s0092-8674(01)00576-1 · Cited by 1,287
p21 is necessary for the p53-mediated G1 arrest in human cancer cells.
Waldman, T. A., Kinzler, K. W., & Vogelstein, B. (1995) · PubMed · Cited by 1,188
Caplen, N. J., Parrish, S., Imani, F., Fire, A. Z., & Morgan, R. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171251798 · Cited by 1,042
Oncogenic Forms of p53 Inhibit p53-Regulated Gene Expression
Kern, S. E., Pietenpol, J., Thiagalingam, S., Seymour, A., Kinzler, K. W., & Vogelstein, B. (1992) · Science · doi:10.1126/science.1589764 · Cited by 940
Gain of function mutations in p53
Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., & Levine, A. J. (1993) · Nature Genetics · doi:10.1038/ng0593-42 · Cited by 894
Identification of essential genes in cultured mammalian cells using small interfering RNAs
Harborth, J., Elbashir, S. M., Bechert, K., Tuschl, T., & Weber, K. K. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.24.4557 · Cited by 828
siRNA-directed inhibition of HIV-1 infection
Novina, C. D., Murray, M. F., Dykxhoorn, D. M., Beresford, P. J., Riess, J. W., Lee, S., Collman, R. G., Lieberman, J., Shankar, P., & Sharp, P. A. (2002) · Nature Medicine · doi:10.1038/nm725 · Cited by 775
Aas, T., Børresen‐Dale, A., Geisler, S. B., Smith‐Sørensen, B., Johnsen, H., Varhaug, J. E., Akslen, L. A., & Lønning, P. E. (1996) · Nature Medicine · doi:10.1038/nm0796-811 · Cited by 736
RNA interference—2001Preprint
Sharp, P. A. (2001) · Genes & Development · doi:10.1101/gad.880001 · Cited by 715
Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
Sigal, A., & Rotter, V. (2000) · PubMed · Cited by 669
Rescuing the function of mutant p53
Bullock, A. N., & Fersht, A. R. (2001) · Nature reviews. Cancer · doi:10.1038/35094077 · Cited by 579
The Human Papillomavirus E6 protein and its contribution to malignant progression
Mantovani, F., & Banks, L. (2001) · Oncogene · doi:10.1038/sj.onc.1204869 · Cited by 519
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour
Marín, M. C., Jost, C. A., Brooks, L. A., Irwin, M. S., O’Nions, J., TIDY, J. A., James, N. D., McGregor, J., Harwood, C. A., Yuluğ, I. G., et al. (2000) · Nature Genetics · doi:10.1038/75586 · Cited by 511
p73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells
Como, C. J. D., Gaiddon, C., & Prives, C. L. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1438 · Cited by 417
RNAi as Random Degradative PCR
Lipardi, C., Qin, W., & Paterson, B. M. (2001) · Cell · doi:10.1016/s0092-8674(01)00537-2 · Cited by 373
Transcriptional gene silencing in plants: targets, inducers and regulators
Vaucheret, H., & Fagard, M. (2001) · Trends in Genetics · doi:10.1016/s0168-9525(00)02166-1 · Cited by 368
Activation of the p53 tumor suppressor protein
Vousden, K. H. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00035-5 · Cited by 337
Multiple roles of the tumor suppressor p53
Bargonetti, J., & Manfredi, J. J. (2002) · Current Opinion in Oncology · doi:10.1097/00001622-200201000-00015 · Cited by 332
Bischoff, F. Z., Yim, S. O., Pathak, S., Grant, G., Siciliano, M. J., Giovanella, B. C., Strong, L. C., & Tainsky, M. A. (1990) · PubMed · Cited by 252
Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73
Strano, S., Munarriz, E. R., Rossi, M., Cristofanelli, B., Shaul, Y., Castagnoli, L., Levine, A. J., Sacchi, A., Cesareni, G., Oren, M., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003360200 · Cited by 241
Harvey, M., Vogel, H. S., Morris, D. K., Bradley, A., Bernstein, A., & Donehower, L. A. (1995) · Nature Genetics · doi:10.1038/ng0395-305 · Cited by 232
Nishikura, K. (2001) · Cell · doi:10.1016/s0092-8674(01)00581-5 · Cited by 174
Davison, T. S., Vagner, C., Kaghad, M., Ayed, A., Caput, D., & Arrowsmith, C. H. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.26.18709 · Cited by 161
Therapeutic exploitation of the p53 pathway
Lane, D. P., & Laı́n, S. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02309-2 · Cited by 127
Isoform-specific knockdown and expression of adaptor protein ShcA using small interfering RNA
Kisielow, M., Kleiner, S., Nagasawa, M., Faisal, A., & Nagamine, Y. (2002) · Biochemical Journal · doi:10.1042/0264-6021:3630001 · Cited by 96
Kitami, T., & Nadeau, J. H. (2002) · Nature Genetics · doi:10.1038/ng1202-681a · Cited by 79
Isoform-specific knockdown and expression of adaptor protein ShcA using small interfering RNA
Kisielow, M., Kleiner, S., Nagasawa, M., et al. (2002) · Biochemical Journal · doi:10.1042/bj3630001 · Cited by 65
Birch, J. M. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)00383-g · Cited by 57
Cyclin E Restores p53 Activity in Contact-Inhibited Cells
Deffie, A. M., Hao, M., Luna, R. M. D. O., Hulboy, D. L., & Lozano, G. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.7.3926 · Cited by 28
Self-citationJõers, A., Kristjuhan, A., Kadaja, L., & Maimets, T. (1998) · Oncogene · doi:10.1038/sj.onc.1202146 · Cited by 21
Research works printed but not linked: 5
- Vousden K. H. (2002) Biochim. Biophys. Acta1602,47-59.11960694
- 10.1126/science.256.5058.827 · DOI
- Sigal A. & Rotter, V. (2000) Cancer Res.60,6788-6793.11156366
- Bischoff F. Z., Yim, S. O., Pathak, S., Grant, G., Siciliano, M. J., Giovanella, B. C., Strong, L. C. & Tainsky, M. A. (1990) Cancer Res.50,7979-7984.2253239
- Waldman T., Kinzler, K. W. & Vogelstein, B. (1995) Cancer Res.55,5187-5190.7585571
Cited by
Sorted by citations
MicroRNA targets in Drosophila
Enright, A. J., John, B., Gaul, U., Tuschl, T., Sander, C., & Marks, D. S. (2003) · Genome Biology · doi:10.1186/gb-2003-5-1-r1 · Cited by 3,597
Expression profiling reveals off-target gene regulation by RNAi
Jackson, A. L., Bartz, S. R., Schelter, J., Kobayashi, S. V., Burchard, J., Mao, M., Li, B., Cavet, G., & Linsley, P. S. (2003) · Nature Biotechnology · doi:10.1038/nbt831 · Cited by 2,370
Small silencing RNAs: an expanding universe
Ghildiyal, M., & Zamore, P. D. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2504 · Cited by 2,418
A biochemical framework for RNA silencing in plantsPreprint
Tang, G., Reinhart, B. J., Bartel, D. P., & Zamore, P. D. (2003) · Genes & Development · doi:10.1101/gad.1048103 · Cited by 994
Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting
Borrero, L. J. H., & El‐Deiry, W. S. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188556 · Cited by 805
Metadata
- Authors
- Martinez, L. A., Naguibneva, I., Lehrmann, H., Vervisch, A., Tchénio, T., Lozano, G., & Harel-Bellan, A.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Scripps Research Institute (US)
- Unité Propre de Recherche 9079, Centre National de la Recherche Scientifique-Ligue Nationale Contre le Cancer, Service de Cytofluorométrie, Unité Propre de Recherche 1983, Centre National de la Recherche Scientifique, Institut André Lwoff, 7 Rue Guy Moquet, 94800 Villejuif, France; and University of Texas M. D. Anderson Cancer Center, Department of Molecular Genetics, Section of Cancer Genetics, 1515 Holcombe Boulevard, Houston, TX 77030
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2002-10-28
- Volume
- 99
- Issue
- 23
- Pages
- 14849-14854
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC137507
- OpenAlex
- W2017991840
- Cited by
- 210
- References
- 40
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 3 · 2022: 4 · 2021: 4 · 2020: 3 · 2019: 6 · 2018: 5 · 2017: 7 · 2016: 2 · 2015: 4 · 2014: 6 · 2013: 5 · 2012: 8
- FWCI
- 7.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Association pour la Recherche sur le Cancer
- Philippe Foundation
- National Cancer Institute (CA09212502)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
- Keywords
- siRNA, p53, point mutations, tumor suppressor, oncogenes, cancer therapy, precision oncology, gene expression inhibition
- MeSH terms
- Base Sequence, Humans, Mutation, Gene Expression Regulation, Neoplastic, Genes, p53, Tumor Suppressor Protein p53, Point Mutation, RNA, Small Interfering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
